Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 1, 2012, Pages 143-148

  Johansson, Daniella ^a   Falk, Aki ^a   Marcus, Monica M ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anti inflammatory; COX 2 inhibition; Major depressive disorder; Medial prefrontal cortex; Microdialysis

Indexed keywords

CELECOXIB; DOPAMINE; FLUOXETINE; NORADRENALIN; REBOXETINE; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; IN VIVO STUDY; MALE; MICRODIALYSIS; NEUROBIOLOGY; NONHUMAN; NORADRENALIN BRAIN LEVEL; PREFRONTAL CORTEX; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CYCLOOXYGENASE 2 INHIBITORS; DOPAMINE; DRUG SYNERGISM; FLUOXETINE; MALE; MICRODIALYSIS; MORPHOLINES; NOREPINEPHRINE; PREFRONTAL CORTEX; PYRAZOLES; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SULFONAMIDES;

EID: 84864506490     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.06.003     Document Type: Article

References (56)

1. Aid S., Bosetti F. Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 2011, 93:46-51.
2. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009, 26:607-611.
3. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington DC. 4th edn.
4. Atre-Vaidya N., Taylor M.A., Seidenberg M., Reed R., Perrine A., Glick-Oberwise F. Cognitive deficits, psychopathology, and psychosocial functioning in bipolar mood disorder. Neuropsychiatry Neuropsychol Behav Neurol 1998, 11:120-126.
5. Belmaker R.H., Agam G. Major depressive disorder. N Engl J Med 2008, 358:55-68.
6. Braun D., Longman R.S., Albert M.L. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005, 106(7):2375-2381.
7. Byrne G.I., Lehmann L.K., Kirschbaum J.G., Borden E.C., Lee C.M., Brown R.R. Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res 1986, 6(4):389-396.
8. Calabrese J.R., Skwerer R.G., Barna B., Gulledge A.D., Valenzuela R., Butkus A., et al. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res 1986, 17:41-47.
9. Carboni E., Tanda G.L., Frau R., Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 1990, 55:1067-1070.
10. Carlsson A. Monoamine-depleting drugs. Pharmacol Ther B 1975, 1:393-400.
11. Casolini P., Catalani A., Zuena A.R., Angelucci L. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 2002, 68:337-343.
12. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
13. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990, 47:411-418.
14. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67(5):446-457.
15. Folkersma H., Breve J.J., Tilders F.J., Cherian L., Robertson C.S., Vandertop W.P. Cerebral microdialysis of interleukin (IL)-1beta and IL-6: extraction efficiency and production in the acute phase after severe traumatic brain injury in rats. Acta Neurochir (Wien) 2008, 150:1277-1284.
16. Garcia-Bueno B., Serrats J., Sawchenko P.E. Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli. J Neurosci 2009, 29:12970-12981.
17. Goodwin F.K., Bunney W.E. Depressions following reserpine: a reevaluation. Semin Psychiatry 1971, 3:435-448.
18. Gunther J., Schulte K., Wenzel D., Malinowska B., Schlicker E. Prostaglandins of the E series inhibit monoamine release via EP3 receptors: proof with the competitive EP3 receptor antagonist L-826,266. Naunyn Schmiedebergs Arch Pharmacol 2010, 381:21-31.
19. Guo J.Y., Li C.Y., Ruan Y.P., Sun M., Qi X.L., Zhao B.S., et al. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 2009, 612:54-60.
20. Harmer C.J., Goodwin G.M., Cowen P.J. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 2009, 195(2):102-108.
21. Harmer C.J., O'Sullivan U., Favaron E., Massey-Chase R., Ayres R., Reinecke A., et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry 2009, 166(10):1178-1184.
22. Heyes M.P., Saito K., Markey S.P. Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 1992, 283:633-635.
23. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur Psychiatry 2002, 17(Suppl. 3):294-299.
24. Ignatowski T.A., Spengler R.N. Tumor necrosis factor-alpha: presynaptic sensitivity is modified after antidepressant drug administration. Brain Res 1994, 665:293-299.
25. Kahl K.G., Bens S., Ziegler K., Rudolf S., Dibbelt L., Kordon A., et al. Cortisol, the cortisol-dehydroepiandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. Biol Psychiatry 2006, 59(7):667-671.
26. Kasper S., el Giamal N., Hilger E. Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother 2000, 1:771-782.
27. Kostowski W. Possible relationship of the locus coeruleus-hippocampal noradrenergic neurons to depression and mode of action of antidepressant drugs. Pol J Pharmacol Pharm 1985, 37:727-743.
28. Kraus M.R., Schafer A., Al-Taie O., Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005, 12:96-100.
29. Kubera M., Maes M. Serotonin-immune interactions in major depression. Neuro-immune interactions in neurologic and psychiatric disorders 2000, 79-87. Springer-Verlag, Berlin. P.H. Patterson, C. Kordon, Y. Christen (Eds.).
30. Leonard B.E., Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol 2009, 24:165-175.
31. Licinio J., Kling M.A., Hauser P. Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Semin Oncol 1998, 25:30-38.
32. Lieb J., Karmali R., Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med 1983, 10:361-367.
33. Linner L., Endersz H., Ohman D., Bengtsson F., Schalling M., Svensson T.H. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 2001, 297:540-546.
34. Linner L., Wiker C., Arborelius L., Schalling M., Svensson T.H. Selective noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release in the rat forebrain. J Neural Transm 2004, 111:127-139.
35. Martinez-Aran A., Vieta E., Reinares M., Colom F., Torrent C., Sanchez-Moreno J., et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004, 161:262-270.
36. Mellor A.L., Munn D.H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. Immunol Today 1999, 20:469-473.
37. Muller N., Riedel M., Schwarz M.J. Psychotropic effects of COX-2 inhibitors-a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry 2004, 37:266-269.
38. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11:680-684.
39. Murphy S.E., Norbury R., O'Sullivan U., Cowen P.J., Harmer C.J. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 2009, 194(6):535-540.
40. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
41. Myint A.M., Steinbusch H.W., Goeghegan L., Luchtman D., Kim Y.K., Leonard B.E. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 2007, 14:65-71.
42. Nery F.G., Monkul E.S., Hatch J.P., Fonseca M., Zunta-Soares G.B., Frey B.N., et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008, 23:87-94.
43. O'Connor J.C., Andre C., Wang Y., Lawson M.A., Szegedi S.S., Lestage J., et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009, 29(13):4200-4209.
44. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego, USA. 4th edition.
45. Reynolds J.L., Ignatowski T.A., Spengler R.N. Effect of tumor necrosis factor-alpha on the reciprocal G-protein-induced regulation of norepinephrine release by the alpha2-adrenergic receptor. J Neurosci Res 2005, 79:779-787.
46. Reynolds J.L., Ignatowski T.A., Sud R., Spengler R.N. An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience 2005, 133:519-531.
47. Schaefer M., Schwaiger M., Garkisch A.S., Pich M., Hinzpeter A., Uebelhack R., et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005, 42:793-798.
48. Song C., Leonard B.E. Fundamentals of neuropsychoimmunlogy 2000, John Wiley & Sons, Chichester, NY.
49. Svensson T.H. Brain noradrenaline and the mechanisms of action of antidepressant drugs. Acta Psychiatr Scand Suppl 2000, 402:18-27.
50. Svensson T.H., Bunney B.S., Aghajanian G.K. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res 1975, 92:291-306.
51. Svensson T.H., Usdin T. Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants: alpha-receptor mediation. Science 1978, 202:1089-1091.
52. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., O'Brien J.T. Increase in interleukin-1beta in late-life depression. Am J Psychiatry 2005, 162:175-177.
53. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
54. WHO, World Health Organization Mental Collaborating Centres Pharmacotherapy of depressive disorders: a consensus statement. J Affect Disord 1989, 17:197-198.
55. Yaksh T.L., Dirig D.M., Conway C.M., Svensson C., Luo Z.D., Isakson P.C. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001, 21:5847-5853.
56. Yermakova A., O'Banion M.K. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des 2000, 6:1755-1776.